Abstract
Purpose
Hyperuricemia (HUA) and hypertriglyceridemia (HTG) were very common in chronic kidney disease (CKD) and associated with accelerated progression of CKD. This was a retrospective, cross-sectional study which aimed to explore the relationship between serum uric acid levels or triglyceride levels and tubular atrophy/interstitial fibrosis (proven by renal biopsy).
Methods
The present study enrolled 229 CKD individuals who included 127 biopsy-proven primary IgA nephrology (IgAN) patients and 102 biopsy-proven primary membranous nephropathy (MN) patients. The baseline characteristics at the time of the kidney biopsy were collected. According to the serum uric acid (UA) or triglyceride (TG) whether it exceeds the normal reference range, patients were divided into non-HUA (n = 127), HUA (n = 102), non-HTG (n = 119), and HTG group (n = 110). Based on the extent of tubular atrophy/interstitial fibrosis, patients were divided into no/mild injury (T0, n = 127), moderate injury (T1, n = 102). Multivariable logistic regression for factors predicting moderate tubular atrophy/interstitial fibrosis was performed.
Results
There were 127 IgAN and 102 MN cases among 229 patients in the present study. The prevalence of HUA was 44.5% (n = 102), 40.9% (n = 52), and 49.0% (n = 50) in all patients, IgAN patients and MN patients, respectively (P = 1.49). The prevalence of HTG was 48.0% (n = 110), 29.9% (n = 38), and 70.6% (n = 72) (P < 0.001), respectively, as well. Multivariate logistic regression analysis showed that HUA and HTG were independent risk factors for moderate tubular atrophy/interstitial fibrosis (HUA OR = 2.335, 95% CI = 1.147–4.755, P = 0.019; HTG OR = 2.646, 95% CI = 1.289–5.432, P = 0.008). The area under curve (AUC) of model 1 (HUA + eGFR + HTG + age + serum globulin + 24 h urinary protein, AUC = 0.876) was larger than the other two models; however, there was no significant difference among these models (all P > 0.05).
Conclusions
Hyperuricemia and hypertriglyceridemia, which were prevalent in CKD patients, were the independent risk factors for moderate tubular atrophy/interstitial fibrosis. HUA together with HTG could improve the value of diagnosis for moderate tubular atrophy/interstitial fibrosis to some extent.
Similar content being viewed by others
Data availability
It is possible if wanted.
References
Li L, Yang C, Zhao Y et al (2014) Is hyperuricemia an independent risk factor for new-onset chronic kidney disease? A systematic review and meta-analysis based on observational cohort studies. BMC Nephrol 15:122
Tsuruya K, Yoshida H, Nagata M et al (2017) Association of hypertriglyceridemia with the incidence and progression of chronic kidney disease and modification of the association by daily alcohol consumption. J Ren Nutr 27(6):381–394
Tsuruya K, Yoshida H, Nagata M et al (2015) Impact of the triglycerides to high-density lipoprotein cholesterol ratio on the incidence and progression of ckd: a longitudinal study in a large Japanese population. Am J Kidney Dis 66(6):972–983
Xue N, Fang Y, Ding X et al (2019) Serum triglycerides are related to chronic kidney disease (CKD) stage 2 in young and middle-aged chinese individuals during routine health examination. Med Sci Monit 25:2445–2451
Toth PP, Philip S, Hull M et al (2019) Elevated triglycerides (≥150 mg/dL) and high triglycerides (200–499 mg/dl) are significant predictors of hospitalization for new-onset kidney disease: a real-world analysis of high-risk statin-treated patients. CardioRenal Med 9(6):400–407
Tsai CW, Lin SY, Kuo CC et al (2017) Serum uric acid and progression of kidney disease: a longitudinal analysis and mini-review. PLoS ONE 12(1):e170393
Hsieh YP, Chang CC, Yang Y et al (2017) The role of uric acid in chronic kidney disease patients. Nephrology 22(6):441–448
Weaver DJ (2019) Uric acid and progression of chronic kidney disease. Pediatr Nephrol 34(5):801–809
Caliskan Y, Ozluk Y, Celik D et al (2016) The clinical significance of uric acid and complement activation in the progression of IgA nephropathy. Kidney Blood Press Res 41(2):148–157
Zhu B, Yu DR, Lv JC et al (2018) Uric acid as a predictor of immunoglobulin a nephropathy progression: a cohort study of 1965 cases. Am J Nephrol 48(2):127–136
Syrjanen J, Mustonen J, Pasternack A (2000) Hypertriglyceridaemia and hyperuricaemia are risk factors for progression of IgA nephropathy. Nephrol Dial Transplant 15(1):34–42
Wang J, He L, Yan W et al (2020) The role of hypertriglyceridemia and treatment patterns in the progression of IgA nephropathy with a high proportion of global glomerulosclerosis. Int Urol Nephrol 52(2):325–335
Moorhead JF, Chan MK, El-Nahas M et al (1982) Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet 2(8311):1309–1311
Srivastava A, Kaze AD, McMullan CJ et al (2018) Uric acid and the risks of kidney failure and death in individuals with CKD. Am J Kidney Dis 71(3):362–370
Madero M, Sarnak MJ, Wang X et al (2009) Uric acid and long-term outcomes in CKD. Am J Kidney Dis 53(5):796–803
Waring WS, Webb DJ, Maxwell SR (2001) Systemic uric acid administration increases serum antioxidant capacity in healthy volunteers. J Cardiovasc Pharmacol 38(3):365–371
Berkowitz D (1964) Blood lipid and uric acid interrelationships. JAMA 190:856–858
Peng TC, Wang CC, Kao TW et al (2015) Relationship between hyperuricemia and lipid profiles in US adults. Biomed Res Int 2015:127596
Zheng R, Ren P, Chen Q et al (2017) Serum uric acid levels and risk of incident hypertriglyceridemia: a longitudinal population-based epidemiological study. Ann Clin Lab Sci 47(5):586–591
Kuwabara M, Borghi C, Cicero A et al (2018) Elevated serum uric acid increases risks for developing high LDL cholesterol and hypertriglyceridemia: a five-year cohort study in Japan. Int J Cardiol 261:183–188
Roberts IS, Cook HT, Troyanov S et al (2009) The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int 76(5):546–556
Cattran DC, Coppo R, Cook HT et al (2009) The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int 76(5):534–545
National Kidney Foundation (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39(2 Suppl 1):S1–S266
Levey AS, Stevens LA, Schmid CH et al (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150(9):604–612
Ruan Y, Hong F, Wu J et al (2018) Clinicopathological characteristics, role of immunosuppressive therapy and progression in IgA nephropathy with hyperuricemia. Kidney Blood Press Res 43(4):1131–1140
Fan S, Zhang P, Wang AY et al (2019) Hyperuricemia and its related histopathological features on renal biopsy. BMC Nephrol 20(1):95
Zhou J, Chen Y, Liu Y et al (2014) Plasma uric acid level indicates tubular interstitial leisions at early stage of IgA nephropathy. BMC Nephrol 15:11
Myllymaki J, Honkanen T, Syrjanen J et al (2005) Uric acid correlates with the severity of histopathological parameters in IgA nephropathy. Nephrol Dial Transplant 20(1):89–95
Ames BN, Cathcart R, Schwiers E et al (1981) Uric acid provides an antioxidant defense in humans against oxidant and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci USA 78(11):6858–6862
Glantzounis GK, Tsimoyiannis EC, Kappas AM et al (2005) Uric acid and oxidative stress. Curr Pharm Des 11(32):4145–4151
Yang D, Su Z, Wu S et al (2016) Low antioxidant status of serum bilirubin, uric acid, albumin and creatinine in patients with myasthenia gravis. Int J Neurosci 126(12):1120–1126
Ljubisavljevic S, Stojanovic I, Vojinovic S et al (2013) Association of serum bilirubin and uric acid levels changes during neuroinflammation in patients with initial and relapsed demyelination attacks. Metab Brain Dis 28(4):629–638
Zhou Y, Fang L, Jiang L et al (2012) Uric acid induces renal inflammation via activating tubular NF-kappaB signaling pathway. PLoS ONE 7(6):e39738
Kurts C (2013) A crystal-clear mechanism of chronic kidney disease. Kidney Int 84(5):859–861
Yu MA, Sanchez-Lozada LG, Johnson RJ et al (2010) Oxidative stress with an activation of the renin-angiotensin system in human vascular endothelial cells as a novel mechanism of uric acid-induced endothelial dysfunction. J Hypertens 28(6):1234–1242
Corry DB, Eslami P, Yamamoto K et al (2008) Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. J Hypertens 26(2):269–275
Zoccali C, Maio R, Mallamaci F et al (2006) Uric acid and endothelial dysfunction in essential hypertension. J Am Soc Nephrol 17(5):1466–1471
Mallat SG, Al KS, Tanios BY et al (2016) Hyperuricemia, hypertension, and chronic kidney disease: an emerging association. Curr Hypertens Rep 18(10):74
Ryu ES, Kim MJ, Shin HS et al (2013) Uric acid-induced phenotypic transition of renal tubular cells as a novel mechanism of chronic kidney disease. Am J Physiol Renal Physiol 304(5):F471–F480
Du XG, Ruan XZ (2019) Lipid metabolism disorder and renal fibrosis. Adv Exp Med Biol 1165:525–541
Sanchez-Lozada LG, Tapia E, Santamaria J et al (2005) Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. Kidney Int 67(1):237–247
Sanchez-Lozada LG, Tapia E, Soto V et al (2008) Treatment with the xanthine oxidase inhibitor febuxostat lowers uric acid and alleviates systemic and glomerular hypertension in experimental hyperuricaemia. Nephrol Dial Transplant 23(4):1179–1185
Goicoechea M, de Vinuesa SG, Verdalles U et al (2010) Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 5(8):1388–1393
Acknowledgements
All of the authors declare that they have no conflict of interest. We thank all the patients involved in this study.
Funding
None.
Author information
Authors and Affiliations
Contributions
XS and BL designed this study; BL, LZ, QY, and DZ collected the data; BL contributed to the statistical analysis; BL drafted manuscript; XS, DZ, and BL revised the manuscript. All authors approved the final version.
Corresponding author
Ethics declarations
Conflict of interest
All of the authors declare that they have no conflict of interest.
Ethical approval
This is an observational study. The Medical Ethics Committee of the Zhongnan Hospital of Wuhan University has confirmed that no ethical approval is required.
Informed consent
Written informed consent was obtained from all participants.
Consent for publication
All of the authors declare their consent for publication.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Liu, B., Zhao, L., Yang, Q. et al. Hyperuricemia and hypertriglyceridemia indicate tubular atrophy/interstitial fibrosis in patients with IgA nephropathy and membranous nephropathy. Int Urol Nephrol 53, 2321–2332 (2021). https://doi.org/10.1007/s11255-021-02844-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11255-021-02844-4